About Bioatla (BCAB)
BioAtla, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing our novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.
- USD3.12
- USD3.16
- USD2.82
- USD4.02
- 11.90%
- --
- 572.58k
- 849.64k
- 130M
- 1.24
- -19.40%
Stock News
2 hours ago
Dow Jones Futures Loom; All Eyes On Nvidia, 5 AI Stocks Near Buy Points
Yahoo
3 hours ago
Dow at 40,000: Why stocks still have 'plenty of room to run'
Yahoo
3 hours ago
7 Ways Costco Can Help You Stretch Your Social Security Checks
Yahoo
4 hours ago
Amazon CEO: An 'embarrassing' amount of your success depends on this one skill
CNBC
Unlock More Stock Analysis & Reports
Access detailed stock analysis from LSEG including analyst price target estimates.
